• 9249 Citations
  • 31 Scopus h-Index
20022020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

DeLeon, T. T., Almquist, D. R., Kipp, B. R., Langlais, B. T., Mangold, A., Winters, J. L., Kosiorek, H. E., Joseph, R. W., Dronca, R. S., Block, M. S., McWilliams, R. R., Kottschade, L. A., Rumilla, K. M., Voss, J. S., Seetharam, M., Sekulic, A., Markovic, S. N. & Bryce, A. H., Jan 1 2020, In : PloS one. 15, 3, e0230306.

Research output: Contribution to journalArticle

Open Access

Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma

Pal, S. K., McDermott, D. F., Atkins, M. B., Escudier, B., Rini, B. I., Motzer, R. J., Fong, L., Joseph, R. W., Oudard, S., Ravaud, A., Bracarda, S., Suárez, C., Lam, E. T., Choueiri, T. K., Ding, B., Quach, C., Hashimoto, K., Schiff, C., Piault-Louis, E. & Powles, T., Jan 1 2020, (Accepted/In press) In : BJU international.

Research output: Contribution to journalArticle

2019

Cutaneous melanoma, version 2.2019

Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Fields, R. C., Fleming, M. D., Freeman, M., Galan, A., Gastman, B., Guild, V., Johnson, D., Joseph, R. W., Lange, J. R., Nath, S., Olszanski, A. J., Ott, P. & 10 others, Gupta, A. P., Ross, M. I., Salama, A. K., Skitzki, J., Sosman, J., Swetter, S. M., Tanabe, K. K., Wuthrick, E., McMillian, N. R. & Engh, A. M., Apr 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 4, p. 367-402 36 p.

Research output: Contribution to journalReview article

Open Access
31 Scopus citations

Desmoplastic melanoma: a brief review and the efficacy of immunotherapy

Ochoa, C. E. & Joseph, R. W., Mar 4 2019, In : Expert Review of Anticancer Therapy. 19, 3, p. 205-207 3 p.

Research output: Contribution to journalEditorial

3 Scopus citations

Drug-associated vasculitis occurring after treatment with pembrolizumab

Tolaymat, O. A., Pinkston, O., Wang, B., Schenk, W. B., Joseph, R. W., Mergo, P. J. & Berianu, F., Aug 1 2019, In : Rheumatology (United Kingdom). 58, 8, p. 1501-1503 3 p.

Research output: Contribution to journalLetter

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., Dronca, R., Mitchell, T. C., Patnaik, A., Zarour, H. M., Joshua, A. M., Zhao, Q., Jensen, E., Ahsan, S., Ibrahim, N. & Ribas, A., Jan 1 2019, In : Annals of Oncology. 30, 4, p. 582-588 7 p., mdz011.

Research output: Contribution to journalArticle

Open Access
52 Scopus citations

Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report

Khurana, S., Baldeo, C. & Joseph, R. W., Jun 1 2019, In : Melanoma research. 29, 3, p. 322-324 3 p.

Research output: Contribution to journalArticle

1 Scopus citations

Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment

Liu, F. X., Witt, E. A., Ebbinghaus, S., Dibonaventura Beyer, G., Basurto, E. & Joseph, R. W., Jan 1 2019, In : Cancer Nursing. 42, 1, p. E52-E59

Research output: Contribution to journalArticle

3 Scopus citations

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Rini, B. I., Battle, D., Figlin, R. A., George, D. J., Hammers, H., Hutson, T., Jonasch, E., Joseph, R. W., McDermott, D. F., Motzer, R. J., Pal, S. K., Pantuck, A. J., Quinn, D. I., Seery, V., Voss, M. H., Wood, C. G., Wood, L. S. & Atkins, M. B., Dec 20 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 354.

Research output: Contribution to journalArticle

Open Access
2 Scopus citations
2018

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Sonbol, M. B., Firwana, B., Hilal, T., Wang, Z., Almader-Douglas, D., Joseph, R. W. & Ho, T. H., Jun 2018, In : European Urology Oncology. 1, 2, p. 101-108 8 p.

Research output: Contribution to journalReview article

2 Scopus citations

Association between programmed death-Ligand 1 expression and the vascular endothelial growth factor pathway in angiosarcoma

Bagaria, S. P., Gatalica, Z., Maney, T., Serie, D., Parasramka, M., Attia, S., Krishna, M. & Joseph, R. W., Mar 22 2018, In : Frontiers in Oncology. 8, MAR, 71.

Research output: Contribution to journalArticle

4 Scopus citations

Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P., Perrone, A., Zhang, J., Kang, S. P., Ebbinghaus, S. & 2 others, Anderson, K. M. & Gangadhar, T. C., Oct 15 2018, In : Clinical Cancer Research. 24, 20, p. 4960-4967 8 p.

Research output: Contribution to journalArticle

51 Scopus citations

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., Sznol, M., Hainsworth, J., Rathmell, W. K., Stadler, W. M., Hutson, T., Gore, M. E., Ravaud, A., Bracarda, S., Suárez, C., Danielli, R. & 12 others, Gruenwald, V., Choueiri, T. K., Nickles, D., Jhunjhunwala, S., Piault-Louis, E., Thobhani, A., Qiu, J., Chen, D. S., Hegde, P. S., Schiff, C., Fine, G. D. & Powles, T., Jun 1 2018, In : Nature Medicine. 24, 6, p. 749-757 9 p.

Research output: Contribution to journalArticle

178 Scopus citations

Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Stephen Hodi, F., Hamid, O., Robert, C., Daud, A., Dronca, R. S., Hersey, P., Weber, J. S., Patnaik, A., de Alwis, D. P., Perrone, A., Zhang, J., Peter Kang, S., Ebbinghaus, S. & 2 others, Anderson, K. M. & Gangadhar, T. C., Dec 1 2018, In : Clinical Cancer Research. 24, 23, 1 p.

Research output: Contribution to journalComment/debate

8 Scopus citations

Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma

Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W. J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., Dronca, R., Patnaik, A., Zarour, H., Kefford, R., Hersey, P., Zhang, J., Anderson, J., Diede, S. J., Ebbinghaus, S. & Hodi, F. S., Jun 10 2018, In : Journal of Clinical Oncology. 36, 17, p. 1668-1674 7 p.

Research output: Contribution to journalArticle

110 Scopus citations

Erratum to: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (Nature Medicine, (2018), 24, 6, (749-757), 10.1038/s41591-018-0053-3)

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., Sznol, M., Hainsworth, J., Rathmell, W. K., Stadler, W. M., Hutson, T., Gore, M. E., Ravaud, A., Bracarda, S., Suárez, C., Danielli, R. & 12 others, Gruenwald, V., Choueiri, T. K., Nickles, D., Jhunjhunwala, S., Piault-Louis, E., Thobhani, A., Qiu, J., Chen, D. S., Hegde, P. S., Schiff, C., Fine, G. D. & Powles, T., Jan 1 2018, (Accepted/In press) In : Nature Medicine.

Research output: Contribution to journalArticle

1 Scopus citations

Factors associated with immunotherapy selection in patients with advanced melanoma

Joseph, R. W., Shillington, A. C., Macahilig, C., Diede, S. J., Dave, V., Harshaw, Q. & Liu, F. X., Nov 1 2018, In : Immunotherapy. 10, 16, p. 1361-1369 9 p.

Research output: Contribution to journalArticle

2 Scopus citations

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., Gherardini, P. F., Chmielowski, B., Wang, X., Shintaku, I. P., Wei, C., Sosman, J. A., Joseph, R. W., Postow, M. A., Carlino, M. S., Hwu, W. J. & 5 others, Scolyer, R. A., Messina, J., Cochran, A. J., Long, G. V. & Ribas, A., Jan 18 2018, In : Nature. 553, 7688, p. 347-350 4 p.

Research output: Contribution to journalArticle

80 Scopus citations

Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma

Johnson, D. B., Bordeaux, J., Kim, J. Y., Vaupel, C., Rimm, D. L., Ho, T. H., Joseph, R. W., Daud, A. I., Conry, R. M., Gaughan, E. M., Hernandez-Aya, L. F., Dimou, A., Funchain, P., Smithy, J., Witte, J. S., McKee, S. B., Ko, J., Wrangle, J. M., Dabbas, B., Tangri, S. & 5 others, Lameh, J., Hall, J., Markowitz, J., Balko, J. M. & Dakappagari, N., Nov 1 2018, In : Clinical Cancer Research. 24, 21, p. 5250-5260 11 p.

Research output: Contribution to journalArticle

19 Scopus citations

Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients

Sims, J. R., Grotz, T. E., Pockaj, B. A., Joseph, R. W., Foote, R. L., Otley, C. C., Weaver, A. L., Jakub, J. W. & Price, D. L., Mar 1 2018, In : Surgical Oncology. 27, 1, p. 11-17 7 p.

Research output: Contribution to journalArticle

12 Scopus citations
2017

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., Dawson, N. A., van der Heijden, M. S., Dreicer, R., Srinivas, S., Retz, M. M., Joseph, R. W., Drakaki, A., Vaishampayan, U. N., Sridhar, S. S., Quinn, D. I. & 15 others, Durán, I., Shaffer, D. R., Eigl, B. J., Grivas, P. D., Yu, E. Y., Li, S., Kadel, E. E., Boyd, Z., Bourgon, R., Hegde, P. S., Mariathasan, S., Thåström, A. C., Abidoye, O. O., Fine, G. D. & Bajorin, D. F., Jan 7 2017, In : The Lancet. 389, 10064, p. 67-76 10 p.

Research output: Contribution to journalArticle

623 Scopus citations

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study

Necchi, A., Joseph, R. W., Loriot, Y., Hoffman-Censits, J., Perez-Gracia, J. L., Petrylak, D. P., Derleth, C. L., Tayama, D., Zhu, Q., Ding, B., Kaiser, C. & Rosenberg, J. E., Dec 1 2017, In : Annals of Oncology. 28, 12, p. 3044-3050 7 p.

Research output: Contribution to journalArticle

40 Scopus citations

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor

Eckel-Passow, J. E., Serie, D. J., Cheville, J. C., Ho, T. H., Kapur, P., Brugarolas, J., Thompson, R. H., Leibovich, B. C., Kwon, E. D., Joseph, R. W. & Parker, A. S., Mar 21 2017, In : BMC Urology. 17, 1, p. 1-7 7 p.

Research output: Contribution to journalArticle

9 Scopus citations

Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma

Wang, D. Y., Eroglu, Z., Ozgun, A., Leger, P. D., Zhao, S., Ye, F., Luke, J. J., Joseph, R. W., Haq, R., Ott, P. A., Hodi, F. S., Sosman, J. A., Johnson, D. B. & Buchbinder, E. I., May 1 2017, In : Cancer immunology research. 5, 5, p. 357-362 6 p.

Research output: Contribution to journalArticle

9 Scopus citations

Comprehensive genomic profiling of a rare thyroid follicular dendritic cell sarcoma

Davila, J. I., Starr, J. S., Attia, S., Wang, C., Knudson, R. A., Necela, B. M., Sarangi, V., Sun, Z. D., Ren, Y., Casler, J. D., Menke, D. M., Oliver, G. R., Joseph, R. W., Copland, J. A. III., Parker, A., Kocher, J-P., Thompson, E. A., Smallridge, R. C. & Asmann, Y., Sep 15 2017, In : Rare Tumors. 9, 2, p. 50-53 4 p., 6834.

Research output: Contribution to journalArticle

1 Scopus citations

Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes

Ho, T. H., Serie, D. J., Parasramka, M., Cheville, J. C., Bot, B. M., Tan, W., Wang, L. M., Joseph, R. W., Hilton, T., Leibovich, B. C., Parker, A. & Eckel-Passow, J. E., 2017, In : Annals of Oncology. 28, 3, p. 604-610 7 p.

Research output: Contribution to journalArticle

23 Scopus citations

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

Gangadhar, T. C., Hwu, W. J., Postow, M. A., Hamid, O., Daud, A., Dronca, R. S., Joseph, R. W., O'Day, S. J., Hodi, F. S., Pavlick, A. C., Kluger, H., Oxborough, R. P., Yang, A., Gazdoiu, M., Kush, D. A., Ebbinghaus, S. & Salama, A. K. S., 2017, In : Journal of Immunotherapy. 40, 9, p. 334-340 7 p.

Research output: Contribution to journalArticle

6 Scopus citations

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Zimmer, L., Apuri, S., Eroglu, Z., Kottschade, L. A., Forschner, A., Gutzmer, R., Schlaak, M., Heinzerling, L., Krackhardt, A. M., Loquai, C., Markovic, S. N., Joseph, R. W., Markey, K., Utikal, J. S., Weishaupt, C., Goldinger, S. M., Sondak, V. K., Zager, J. S., Schadendorf, D. & Khushalani, N. I., Apr 1 2017, In : European Journal of Cancer. 75, p. 47-55 9 p.

Research output: Contribution to journalArticle

52 Scopus citations

Multicenter validation of enhancer of zeste homolog 2 expression as an independent prognostic marker in localized clear cell renal cell carcinoma

Ho, T. H., Eckel-Passow, J. E., Cheville, J. C., Houston Thompson, R., Kapur, P., Christie, A., Panwar, V., Brugarolas, J., Homayoun, F., Joseph, R. W., Serie, D. J. & Parker, A. S., Nov 10 2017, In : Journal of Clinical Oncology. 35, 32, p. 3706-3713 8 p.

Research output: Contribution to journalArticle

13 Scopus citations

NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab±everolimus for metastatic melanoma

Mc Williams, R. R., Allred, J. B., Slostad, J. A., Katipamula, R., Dronca, R. S., Rumilla, K. M., Erickson, L. A., Bryce, A. H., Joseph, R. W., Kottschade, L. A., King, D. M., Leitch, J. M. & Markovic, S. N., 2017, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

4 Scopus citations

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice

Joseph, R. W., Chatta, G. & Vaishampayan, U., Apr 1 2017, In : Urologic Oncology: Seminars and Original Investigations. 35, 4, p. 142-148 7 p.

Research output: Contribution to journalReview article

7 Scopus citations

Non–clear cell renal cell carcinomas: Biological insights and therapeutic challenges and opportunities

Malouf, G. G., Joseph, R. W., Shah, A. Y. & Tannir, N. M., May 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 5, p. 409-418 10 p.

Research output: Contribution to journalArticle

4 Scopus citations

Patient and oncologist preferences for attributes of treatments in advanced melanoma: A discrete choice experiment

Liu, F. X., Witt, E. A., Ebbinghaus, S., Beyer, G. D., Shinde, R., Basurto, E. & Joseph, R. W., Aug 14 2017, In : Patient Preference and Adherence. 11, p. 1389-1399 11 p.

Research output: Contribution to journalArticle

6 Scopus citations

The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: A retrospective study

Elias, A. W., Kasi, P. M., Stauffer, J. A., Thiel, D. D., Colibaseanu, D. T., Mody, K., Joseph, R. W. & Bagaria, S. P., Jun 12 2017, In : Frontiers in Oncology. 7, JUN, 121.

Research output: Contribution to journalArticle

16 Scopus citations
2016

Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W. J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R. S., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B. & 8 others, Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P. & Robert, C., Apr 19 2016, In : JAMA - Journal of the American Medical Association. 315, 15, p. 1600-1609 10 p.

Research output: Contribution to journalArticle

454 Scopus citations

A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer

Ho, T. H., Nunez-Nateras, R., Hou, Y. X., Bryce, A. H., Northfelt, D. W., Dueck, A., Wong, B., Stanton, M. L., Joseph, R. W. & Castle, E. P., Jul 8 2016, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

3 Scopus citations

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., Srinivas, S., Retz, M. M., Grivas, P., Joseph, R. W., Galsky, M. D., Fleming, M. T., Petrylak, D. P., Perez-Gracia, J. L., Burris, H. A., Castellano, D. & 11 others, Canil, C., Bellmunt, J., Bajorin, D., Nickles, D., Bourgon, R., Frampton, G. M., Cui, N., Mariathasan, S., Abidoye, O., Fine, G. D. & Dreicer, R., 2016, (Accepted/In press) In : The Lancet.

Research output: Contribution to journalArticle

1514 Scopus citations

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression

Joseph, R. W., Kapur, P., Serie, D. J., Parasramka, M., Ho, T. H., Cheville, J. C., Frenkel, E., Parker, A. & Brugarolas, J., Jan 1 2016, In : Journal of Urology. 195, 1, p. 180-187 8 p.

Research output: Contribution to journalArticle

61 Scopus citations

Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness

Serie, D. J., Joseph, R. W., Cheville, J. C., Ho, T. H., Parasramka, M., Hilton, T., Thompson, R. H., Leibovich, B. C., Parker, A. & Eckel-Passow, J. E., 2016, (Accepted/In press) In : European Urology.

Research output: Contribution to journalArticle

17 Scopus citations

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response

Ho, T. H., Choueiri, T. K., Wang, K., Karam, J. A., Chalmers, Z., Frampton, G., Elvin, J. A., Johnson, A., Liu, X., Lin, Y., Joseph, R. W., Stanton, M. L., Miller, V. A., Stephens, P. J., Ross, J. S., Ali, S. M. & Pal, S. K., Jun 1 2016, In : European Urology Focus. 2, 2, p. 204-209 6 p.

Research output: Contribution to journalArticle

17 Scopus citations

Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis

Zhu, P., Stanton, M. L., Castle, E. P., Joseph, R. W., Adams, D. L., Li, S., Amstutz, P., Tang, C. M. & Ho, T. H., Jul 2 2016, In : Journal of Translational Medicine. 14, 1, 198.

Research output: Contribution to journalArticle

8 Scopus citations

Efficacy of immunotherapy for metastatic mucosal melanoma

Shreders, A. & Joseph, R. W., Jul 1 2016, In : Immunotherapy. 8, 8, p. 843-845 3 p.

Research output: Contribution to journalEditorial

2 Scopus citations

Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab

Hodi, F. S., Hwu, W. J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., Joshua, A. M., Hersey, P., Dronca, R. S., Joseph, R. W., Hille, D., Xue, D., Li, X. N., Kang, S. P., Ebbinghaus, S., Perrone, A. & 1 others, Wolchok, J. D., May 1 2016, In : Journal of Clinical Oncology. 34, 13, p. 1510-1517 8 p.

Research output: Contribution to journalArticle

353 Scopus citations

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death

Ho, T. H., Kapur, P., Joseph, R. W., Serie, D. J., Eckel-Passow, J. E., Tong, P., Wang, J., Castle, E. P., Stanton, M. L., Cheville, J. C., Jonasch, E., Brugarolas, J. & Parker, A., Jan 1 2016, In : Modern Pathology. 29, 1, p. 34-42 9 p.

Research output: Contribution to journalArticle

20 Scopus citations

Melanoma, version 2.2016 clinical practice guidelines in oncology

Coit, D. G., Thompson, J. A., Algazi, A., Andtbacka, R., Bichakjian, C. K., Carson, W. E., Daniels, G. A., DiMaio, D., Ernstoff, M., Fields, R. C., Fleming, M. D., Gonzalez, R., Guild, V., Halpern, A. C., Hodi, F. S., Joseph, R. W., Lange, J. R., Martini, M. C., Materin, M. A., Olszanski, A. J. & 11 others, Ross, M. I., Salama, A. K., Skitzki, J., Sosman, J., Swetter, S. M., Tanabe, K. K., Torres-Roca, J. F., Trisal, V., Urist, M. M., McMillian, N. & Engh, A., Apr 1 2016, In : JNCCN Journal of the National Comprehensive Cancer Network. 14, 4, p. 450-473 24 p.

Research output: Contribution to journalArticle

Open Access
128 Scopus citations

NCCN Guidelines® insights: Melanoma, version 3.2016: Featured updates to the NCCN Guidelines

Coit, D. G., Thompson, J. A., Algazi, A., Andtbacka, R., Bichakjian, C. K., Iii, W. E. C., Daniels, G. A., Dimaio, D., Fields, R. C., Fleming, M. D., Gastman, B., Gonzalez, R., Guild, V., Johnson, D., Joseph, R. W., Lange, J. R., Martini, M. C., Materin, M. A., Olszanski, A. J., Ott, P. & 11 others, Gupta, A. P., Ross, M. I., Salama, A. K., Skitzki, J., Swetter, S. M., Tanabe, K. K., Torres-Roca, J. F., Trisal, V., Urist, M. M., McMillian, N. & Engh, A., Aug 1 2016, In : JNCCN Journal of the National Comprehensive Cancer Network. 14, 8, p. 945-958 14 p.

Research output: Contribution to journalArticle

Open Access
50 Scopus citations

Patient-derived tumor xenograft models for melanoma drug discovery

Harris, A. L., Joseph, R. W. & Copland, J. A. III., Sep 1 2016, In : Expert Opinion on Drug Discovery. 11, 9, p. 895-906 12 p.

Research output: Contribution to journalReview article

6 Scopus citations

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W. J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., Joseph, R. W., Gangadhar, T. C., Dronca, R. S., Patnaik, A., Zarour, H., Roach, C., Toland, G., Lunceford, J. K., Li, X. N., Emancipator, K. & 4 others, Dolled-Filhart, M., Kang, S. P., Ebbinghaus, S. & Hamid, O., Dec 1 2016, In : Journal of Clinical Oncology. 34, 34, p. 4102-4109 8 p.

Research output: Contribution to journalArticle

221 Scopus citations

Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab

Shreders, A., Joseph, R. W., Peng, C., Ye, F., Zhao, S., Puzanov, I., Sosman, J. A. & Johnson, D. B., Jul 1 2016, In : Cancer immunology research. 4, 7, p. 569-573 5 p.

Research output: Contribution to journalReview article

9 Scopus citations

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Rini, B. I., McDermott, D. F., Hammers, H., Bro, W., Bukowski, R. M., Faba, B., Faba, J., Figlin, R. A., Hutson, T., Jonasch, E., Joseph, R. W., Leibovich, B. C., Olencki, T., Pantuck, A. J., Quinn, D. I., Seery, V., Voss, M. H., Wood, C. G., Wood, L. S. & Atkins, M. B., Nov 15 2016, In : Journal for ImmunoTherapy of Cancer. 4, 1, 81.

Research output: Contribution to journalArticle

26 Scopus citations